Platform of Polymeric Conjugates
for Selective Intracorporeal Removal
of Specific Harmful Antibodies
Discovery
PoC
Pre-clinical
Phase I
Phase II
RA0127
70%Antibody-dependent enhancement (ADE) of bacterial infections occurs when blocking antibodies facilitate the infectivity of pathogens. Natural antibodies against Galα1-3Galβ1-4GlcNAcβ (αGal) epitope act as blocking antibodies against Gram-negative bacteria. This phenomenon contributes to the global and increasing the augment of antimicrobial resistance (AMR).The Intensive Care Unit (ICU) is the worst scenario for AMR. Patients admitted to ICUs are at high risk of acquiring infections, mainly by gram-negative bacteria, because of their underlying illness and constant exposure to invasive practices. RA0127 removes anti-αGal antibodies and is developed to protect ICU patients from Gram-negative bacterial infections.
RA0118
50%People exposed to hard tick bites are sensitized to αGal, producing elevated levels of anti-αGal IgE that cause allergic reactions to red meat and monoclonal antibodies used to treat different diseases. The natural habitat of this type of tick is being significantly impacted by climate change, occupying ever larger regions worldwide. RA0118 is a family of polymeric conjugates that selectively removes some types of anti-αGal immunoglobulins for treating allergic disorders.
RA02AB
35%The AB0 blood group antigens are carbohydrate epitopes located on the surfaces of cells. Anti-A and anti-B antibodies bind to the antigens leading to complement fixation and causing intravascular hemolysis of red blood cells in blood transfusion and hyperacute rejection of vascularized organs in organ transplantation. RA02A/RA02B are new carbohydrate derivatives of blood group A and B antigens that bind anti-A and anti-B antibodies, avoiding disorders related to AB0 blood group incompatibility.
RAAV03
45%Gene therapy represents a promising treatment strategy that involves replacing a disease-causing gene with a functional copy, typically delivered using viral vectors such as adeno-associated viruses (AAV). However, the presence of preexisting anti-AAV neutralizing antibodies (NAbs) in patients can hinder the success of these therapies by recognizing and neutralizing the viral vectors, thereby reducing gene transfer efficiency. The use of RAAV03 to intracorporeally remove these antibodies holds significant promise for expanding the pool of eligible patients for gene therapy. Moreover, it could play a pivotal role in enabling safe and effective redosing strategies, which are often compromised by immune responses.
RA06GB
40%Graves-Basedow disease is an autoimmune disorder characterized by the production of autoantibodies targeting the TSH receptor (TRAb), which aberrantly activate the thyroid gland, leading to hyperthyroidism. RA06GB aims to selectively remove anti-TSHR antibodies in order to precisely and effectively restore hormonal levels in patients.